{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:57:55Z","timestamp":1790780275858,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020655","name":"European Health and Digital Executive Agency","doi-asserted-by":"publisher","award":["101057619"],"award-info":[{"award-number":["101057619"]}],"id":[{"id":"10.13039\/100020655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"DOI":"10.1007\/s40258-026-01075-x","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:19:24Z","timestamp":1790777964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An Early Value Assessment of Biomarker-Guided Precision Medicine for Treatment-Resistant Hypertension: A Headroom and Threshold Analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1090-1721","authenticated-orcid":false,"given":"Teebah","family":"Abu-Zahra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirre","family":"Scholte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I.","family":"Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Saliba-Gustafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Parini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Joore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"1075_CR1","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2023.51","volume":"19","author":"G Buso","year":"2024","unstructured":"Buso G, et al. The global burden of resistant hypertension and potential treatment options. Eur Cardiol. 2024;19:e07. https:\/\/doi.org\/10.15420\/ecr.2023.51.","journal-title":"Eur Cardiol"},{"issue":"5","key":"1075_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11906-023-01282-0","volume":"26","author":"JM Flack","year":"2024","unstructured":"Flack JM, Buhnerkempe MG, Moore KT. Resistant hypertension: disease burden and emerging treatment options. Curr Hypertens Rep. 2024;26(5):183\u201399. https:\/\/doi.org\/10.1007\/s11906-023-01282-0.","journal-title":"Curr Hypertens Rep"},{"issue":"38","key":"1075_CR3","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912\u20134018. https:\/\/doi.org\/10.1093\/eurheartj\/ehae178.","journal-title":"Eur Heart J"},{"issue":"2","key":"1075_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","volume":"105","author":"JJ Noubiap","year":"2019","unstructured":"Noubiap JJ, et al. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105(2):98\u2013105. https:\/\/doi.org\/10.1136\/heartjnl-2018-313599.","journal-title":"Heart"},{"issue":"13","key":"1075_CR5","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","volume":"125","author":"SL Daugherty","year":"2012","unstructured":"Daugherty SL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635\u201342. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.068064.","journal-title":"Circulation"},{"issue":"3","key":"1075_CR6","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/ki.2015.142","volume":"88","author":"JJ Sim","year":"2015","unstructured":"Sim JJ, et al. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015;88(3):622\u201332. https:\/\/doi.org\/10.1038\/ki.2015.142.","journal-title":"Kidney Int"},{"issue":"5","key":"1075_CR7","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","volume":"72","author":"RM Carey","year":"2018","unstructured":"Carey RM, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53\u201390. https:\/\/doi.org\/10.1161\/HYP.0000000000000084.","journal-title":"Hypertension"},{"key":"1075_CR8","doi-asserted-by":"publisher","first-page":"1211199","DOI":"10.3389\/fcvm.2023.1211199","volume":"10","author":"MK Champaneria","year":"2023","unstructured":"Champaneria MK, Patel RS, Oroszi TL. When blood pressure refuses to budge: exploring the complexity of resistant hypertension. Front Cardiovasc Med. 2023;10:1211199. https:\/\/doi.org\/10.3389\/fcvm.2023.1211199.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"1075_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.12793\/tcp.2019.27.2.59","volume":"27","author":"K Park","year":"2019","unstructured":"Park K. A review of computational drug repurposing. Transl Clin Pharmacol. 2019;27(2):59\u201363. https:\/\/doi.org\/10.12793\/tcp.2019.27.2.59.","journal-title":"Transl Clin Pharmacol"},{"issue":"2","key":"1075_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.tips.2021.11.004","volume":"43","author":"C Nogales","year":"2022","unstructured":"Nogales C, et al. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol Sci. 2022;43(2):136\u201350. https:\/\/doi.org\/10.1016\/j.tips.2021.11.004.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"1075_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41\u201358. https:\/\/doi.org\/10.1038\/nrd.2018.168.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"1075_CR12","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1007\/s12265-024-10541-7","volume":"17","author":"J Du","year":"2024","unstructured":"Du J, et al. Plasma biomarker screening based on proteomic signature of patients with resistant hypertension. J Cardiovasc Transl Res. 2024;17(6):1286\u201394. https:\/\/doi.org\/10.1007\/s12265-024-10541-7.","journal-title":"J Cardiovasc Transl Res"},{"issue":"1","key":"1075_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s44324-024-00028-z","volume":"2","author":"B Zhang","year":"2024","unstructured":"Zhang B, Schmidlin T. Recent advances in cardiovascular disease research driven by metabolomics technologies in the context of systems biology. NPJ Metab Health Dis. 2024;2(1):25. https:\/\/doi.org\/10.1038\/s44324-024-00028-z.","journal-title":"NPJ Metab Health Dis"},{"issue":"12","key":"1075_CR14","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1093\/eurjpc\/zwad122","volume":"30","author":"PM Haller","year":"2023","unstructured":"Haller PM, et al. Biomarker-based prediction of fatal and non-fatal cardiovascular outcomes in individuals with diabetes mellitus. Eur J Prev Cardiol. 2023;30(12):1218\u201326. https:\/\/doi.org\/10.1093\/eurjpc\/zwad122.","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"1075_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.33963\/KP.a2023.0037","volume":"81","author":"E Jozefczuk","year":"2023","unstructured":"Jozefczuk E, Guzik TJ, Siedlinski M. Novel biomarkers and emerging tools to identify causal molecular pathways in hypertension and associated cardiovascular diseases. Kardiol Pol. 2023;81(3):221\u201331. https:\/\/doi.org\/10.33963\/KP.a2023.0037.","journal-title":"Kardiol Pol"},{"key":"1075_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11112147","author":"J Marques","year":"2022","unstructured":"Marques J, et al. NADPH oxidase 5 (NOX5) overexpression promotes endothelial dysfunction via cell apoptosis, migration, and metabolic alterations in human brain microvascular endothelial cells (hCMEC\/D3). Antioxidants. 2022. https:\/\/doi.org\/10.3390\/antiox11112147.","journal-title":"Antioxidants"},{"issue":"6","key":"1075_CR17","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/j.ajpath.2012.02.018","volume":"180","author":"NE Hahn","year":"2012","unstructured":"Hahn NE, et al. NOX5 expression is increased in intramyocardial blood vessels and cardiomyocytes after acute myocardial infarction in humans. Am J Pathol. 2012;180(6):2222\u20139. https:\/\/doi.org\/10.1016\/j.ajpath.2012.02.018.","journal-title":"Am J Pathol"},{"issue":"4","key":"1075_CR18","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1172\/JCI124283","volume":"129","author":"AI Casas","year":"2019","unstructured":"Casas AI, et al. Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke. J Clin Invest. 2019;129(4):1772\u20138. https:\/\/doi.org\/10.1172\/JCI124283.","journal-title":"J Clin Invest"},{"issue":"11","key":"1075_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000885","volume":"18","author":"MH Elbatreek","year":"2020","unstructured":"Elbatreek MH, et al. NOX5-induced uncoupling of endothelial NO synthase is a causal mechanism and theragnostic target of an age-related hypertension endotype. PLoS Biol. 2020;18(11):e3000885. https:\/\/doi.org\/10.1371\/journal.pbio.3000885.","journal-title":"PLoS Biol"},{"issue":"6","key":"1075_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104008","volume":"29","author":"T Abu-Zahra","year":"2024","unstructured":"Abu-Zahra T, et al. How health technology assessment can help to address challenges in drug repurposing: a conceptual framework. Drug Discov Today. 2024;29(6):104008. https:\/\/doi.org\/10.1016\/j.drudis.2024.104008.","journal-title":"Drug Discov Today"},{"issue":"3","key":"1075_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1017\/S0266462320000215","volume":"36","author":"B O'Rourke","year":"2020","unstructured":"O\u2019Rourke B, et al. The new definition of health technology assessment: a milestone in international collaboration. Int J Technol Assess Health Care. 2020;36(3):187\u201390. https:\/\/doi.org\/10.1017\/S0266462320000215.","journal-title":"Int J Technol Assess Health Care"},{"issue":"2","key":"1075_CR22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1258\/135581904322987535","volume":"9","author":"P Barton","year":"2004","unstructured":"Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy. 2004;9(2):110\u20138. https:\/\/doi.org\/10.1258\/135581904322987535.","journal-title":"J Health Serv Res Policy"},{"issue":"1","key":"1075_CR23","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462321000507","volume":"37","author":"J Bouttell","year":"2021","unstructured":"Bouttell J, Briggs A, Hawkins N. A toolkit of methods of development-focused health technology assessment. Int J Technol Assess Health Care. 2021;37(1):e84. https:\/\/doi.org\/10.1017\/S0266462321000507.","journal-title":"Int J Technol Assess Health Care"},{"issue":"2","key":"1075_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40258-022-00774-5","volume":"21","author":"EA Boudewijns","year":"2023","unstructured":"Boudewijns EA, et al. Headroom analysis for early economic evaluation: a systematic review. Appl Health Econ Health Policy. 2023;21(2):195\u2013204. https:\/\/doi.org\/10.1007\/s40258-022-00774-5.","journal-title":"Appl Health Econ Health Policy"},{"issue":"8","key":"1075_CR25","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s40273-026-01625-0","volume":"44","author":"M Franklin","year":"2026","unstructured":"Franklin M, et al. A systematic literature review of health economic modelling approaches used to evaluate treatment resistant and uncontrolled hypertension: a critical appraisal and considerations for the design of future model analyses. Pharmacoeconomics. 2026;44(8):907\u201335. https:\/\/doi.org\/10.1007\/s40273-026-01625-0.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"1075_CR26","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s40273-025-01515-x","volume":"43","author":"T Abu-Zahra","year":"2025","unstructured":"Abu-Zahra T, et al. Can we make health economic decision models as simple as possible, but not simpler? Introducing SMART tool. Pharmacoeconomics. 2025;43(10):1235\u201350. https:\/\/doi.org\/10.1007\/s40273-025-01515-x.","journal-title":"Pharmacoeconomics"},{"key":"1075_CR27","unstructured":"Assessment, I.f.M.T. Disease Burden Calculator (iDBC). 2023 [cited 2025 08 July]; https:\/\/www.imta.nl\/tools\/idbc\/."},{"key":"1075_CR28","unstructured":"Roijen, L.H.v., Costing manual: Methods and Reference Prices for Economic Evaluations in Healthcare. 2024."},{"issue":"4","key":"1075_CR29","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1177\/0272989X211045070","volume":"42","author":"J Bilcke","year":"2022","unstructured":"Bilcke J, Beutels P. Generating, presenting, and interpreting cost-effectiveness results in the context of uncertainty: a tutorial for deeper knowledge and better practice. Med Decis Making. 2022;42(4):421\u201335. https:\/\/doi.org\/10.1177\/0272989X211045070.","journal-title":"Med Decis Making"},{"key":"1075_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3389\/fpubh.2017.00307","volume":"5","author":"R Trevethan","year":"2017","unstructured":"Trevethan R. Sensitivity, specificity, and predictive values: foundations, pliabilities, and pitfalls in research and practice. Front Public Health. 2017;5:307. https:\/\/doi.org\/10.3389\/fpubh.2017.00307.","journal-title":"Front Public Health"},{"key":"1075_CR31","unstructured":"(WHO), W.h.o. Cardiovascular diseases (CVDs). 2025 [cited 2025 15 October]; https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds)."},{"issue":"1","key":"1075_CR32","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3111\/13696998.2014.978453","volume":"18","author":"TL Henry","year":"2015","unstructured":"Henry TL, et al. Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands. J Med Econ. 2015;18(1):76\u201387. https:\/\/doi.org\/10.3111\/13696998.2014.978453.","journal-title":"J Med Econ"},{"issue":"9756","key":"1075_CR33","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","volume":"376","author":"HTNI Symplicity","year":"2010","unstructured":"Symplicity HTNI, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(10)62039-9.","journal-title":"Lancet"},{"issue":"25","key":"1075_CR34","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","volume":"42","author":"group, S.w.","year":"2021","unstructured":"group, S.w., E.S.C.C.r. collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439\u201354. https:\/\/doi.org\/10.1093\/eurheartj\/ehab309.","journal-title":"Eur Heart J"},{"issue":"25","key":"1075_CR35","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","volume":"42","author":"group, S.O.w.","year":"2021","unstructured":"group, S.O.w., E.S.C.C.r. collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021;42(25):2455\u201367. https:\/\/doi.org\/10.1093\/eurheartj\/ehab312.","journal-title":"Eur Heart J"},{"issue":"1","key":"1075_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.amjmed.2013.07.038","volume":"127","author":"S Bangalore","year":"2014","unstructured":"Bangalore S, et al. Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. Am J Med. 2014;127(1):71-81 e1. https:\/\/doi.org\/10.1016\/j.amjmed.2013.07.038.","journal-title":"Am J Med"},{"issue":"2","key":"1075_CR37","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/eurjpc\/zwad318","volume":"31","author":"TJ van Trier","year":"2024","unstructured":"van Trier TJ, et al. Validation of Systematic Coronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons in the EPIC-Norfolk prospective population cohort. Eur J Prev Cardiol. 2024;31(2):182\u20139. https:\/\/doi.org\/10.1093\/eurjpc\/zwad318.","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"1075_CR38","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40258-014-0116-7","volume":"12","author":"D Gladwell","year":"2014","unstructured":"Gladwell D, et al. Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK. Appl Health Econ Health Policy. 2014;12(6):611\u201322. https:\/\/doi.org\/10.1007\/s40258-014-0116-7.","journal-title":"Appl Health Econ Health Policy"},{"issue":"3","key":"1075_CR39","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1097\/HJH.0000000000000071","volume":"32","author":"O Borisenko","year":"2014","unstructured":"Borisenko O, et al. Cost-effectiveness of Barostim therapy for the treatment of resistant hypertension in European settings. J Hypertens. 2014;32(3):681\u201392. https:\/\/doi.org\/10.1097\/HJH.0000000000000071.","journal-title":"J Hypertens"},{"issue":"10","key":"1075_CR40","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1093\/ajh\/hpy108","volume":"31","author":"EK Chowdhury","year":"2018","unstructured":"Chowdhury EK, et al. Cost-effectiveness of renal denervation therapy for treatment-resistant hypertension: a best case scenario. Am J Hypertens. 2018;31(10):1156\u201363. https:\/\/doi.org\/10.1093\/ajh\/hpy108.","journal-title":"Am J Hypertens"},{"issue":"10022","key":"1075_CR41","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(15)01225-8.","journal-title":"Lancet"},{"key":"1075_CR42","unstructured":"StatLine. Overledenen; belangrijke doodsoorzaken (korte lijst), leeftijd, geslacht. 2025 [cited 2025 22 October]; Overledenen; belangrijke doodsoorzaken (korte lijst), leeftijd, geslacht]. https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/nl\/dataset\/7052_95\/table?ts=1749633977720."},{"issue":"14","key":"1075_CR43","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.jacc.2012.07.029","volume":"60","author":"BP Geisler","year":"2012","unstructured":"Geisler BP, et al. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol. 2012;60(14):1271\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2012.07.029.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"1075_CR44","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1097\/HJH.0000000000003780","volume":"42","author":"VJM Zeijen","year":"2024","unstructured":"Zeijen VJM, et al. Quality-of-life and beliefs about medication in relation to a therapy adherence intervention in resistant hypertension: the Resistant HYpertension: MEasure to ReaCh Targets trial. J Hypertens. 2024;42(10):1687\u201394. https:\/\/doi.org\/10.1097\/HJH.0000000000003780.","journal-title":"J Hypertens"},{"issue":"1","key":"1075_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15083-4","volume":"7","author":"L Zhang","year":"2017","unstructured":"Zhang L, et al. Health-related quality of life among adults with and without hypertension: a population-based survey using EQ-5D in Shandong, China. Sci Rep. 2017;7(1):14960. https:\/\/doi.org\/10.1038\/s41598-017-15083-4.","journal-title":"Sci Rep"},{"key":"1075_CR46","unstructured":"Medicijnkosten. Medicijnkosten. 2025 [cited 2025 05 May]; Available from: https:\/\/www.medicijnkosten.nl\/."},{"key":"1075_CR47","unstructured":"(RIVM), R.v.V.e.M. Kosteneffectiviteit van een screeningsprogramma naar chronische Q-koorts. Series 2017 https:\/\/www.rivm.nl\/bibliotheek\/rapporten\/2017-0127.pdf."},{"key":"1075_CR48","unstructured":"Kompas, F. Farmacotherapeutisch Kompas. 2025 [cited 2025 1 June]; https:\/\/www.farmacotherapeutischkompas.nl\/."},{"issue":"1","key":"1075_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3\u20139. https:\/\/doi.org\/10.1016\/j.jval.2021.11.1351.","journal-title":"Value Health"},{"issue":"11","key":"1075_CR50","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s40273-019-00844-y","volume":"37","author":"NC Buyukkaramikli","year":"2019","unstructured":"Buyukkaramikli NC, et al. TECH-VER: a verification checklist to reduce errors in models and improve their credibility. Pharmacoeconomics. 2019;37(11):1391\u2013408. https:\/\/doi.org\/10.1007\/s40273-019-00844-y.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1075_CR51","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, et al. AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users. Pharmacoeconomics. 2016;34(4):349\u201361. https:\/\/doi.org\/10.1007\/s40273-015-0327-2.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"1075_CR52","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41569-022-00717-6","volume":"19","author":"M Abdelsayed","year":"2022","unstructured":"Abdelsayed M, et al. Repurposing drugs to treat cardiovascular disease in the era of precision medicine. Nat Rev Cardiol. 2022;19(11):751\u201364. https:\/\/doi.org\/10.1038\/s41569-022-00717-6.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"1075_CR53","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12967-021-02910-6","volume":"19","author":"D Hartl","year":"2021","unstructured":"Hartl D, et al. Translational precision medicine: an industry perspective. J Transl Med. 2021;19(1):245. https:\/\/doi.org\/10.1186\/s12967-021-02910-6.","journal-title":"J Transl Med"},{"issue":"2","key":"1075_CR54","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40292-024-00634-4","volume":"31","author":"G Nardoianni","year":"2024","unstructured":"Nardoianni G, et al. Systematic review article: new drug strategies for treating resistant hypertension-the importance of a mechanistic, personalized approach. High Blood Press Cardiovasc Prev. 2024;31(2):99\u2013112. https:\/\/doi.org\/10.1007\/s40292-024-00634-4.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"1","key":"1075_CR55","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462325100123","volume":"41","author":"JPC Grutters","year":"2025","unstructured":"Grutters JPC, et al. Defining early health technology assessment: building consensus using Delphi technique. Int J Technol Assess Health Care. 2025;41(1):e34. https:\/\/doi.org\/10.1017\/S0266462325100123.","journal-title":"Int J Technol Assess Health Care"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-026-01075-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-026-01075-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-026-01075-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:19:27Z","timestamp":1790777967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-026-01075-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":55,"alternative-id":["1075"],"URL":"https:\/\/doi.org\/10.1007\/s40258-026-01075-x","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"26 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing financial or non-financial interests that are directly or indirectly related to the content of this work.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We hereby confirm that all authors of this manuscript have agreed to its content and publication. No patients were involved in this study.","order":4,"name":"Ethics","label":"Consent for Publication (from patients\/participants)","group":{"name":"EthicsHeading","label":"Declarations"}}]}}